New pill could help control blood disorder when standard drugs fail
NCT ID NCT07232290
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This study tests a new drug called flonoltinib maleate in 60 people with polycythemia vera (a condition where the body makes too many red blood cells) who cannot take or no longer respond to standard treatments. The goal is to see if the drug safely reduces red blood cell levels without needing blood removal procedures. The trial has two phases to find the best dose and confirm its effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA (PV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (IHCAMS)
RECRUITINGTianjin, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug outperform standard care for rare blood cancers?
- New drug ZE74-0282 targets rare blood cancers in early trial
- New hope for rare blood cancers: first human trial of PRT12396 begins
- New Pill-and-Shot combo aims to tame thick blood
- Massive new study aims to unlock secrets of rare blood cancers
- Blood thickens during exercise in rare disorder, study aims to find why